hrp0084p3-1079 | Hypo | ESPE2015

Isolated Postprandial Hyperinsulinaemic Hypoglycaemia

Guemes Maria , Melikyan Maria , Senniappan Senthil , Hussain Khalid

Background: Only a few case reports have described isolated postprandial hyperinsulinaemic hypoglycaemia (PPHH) in children.Objectives: To describe a single tertiary paediatric centre’s experience in the management of isolated PPHH.Patients and methods: Six children (three females) were identified. A retrospective review of the clinical characteristics, diagnosis, management and follow-up of patients with PPHH was performed. I...

hrp0084p3-1113 | Pituitary | ESPE2015

A Rare case of Congenital Hyperinsulinism Associated with Hypopituitarism due to Pituitary Stalk Interruption Syndrome

Alsaffar Hussain , Phanse Supriya , Didi Mohammed , Senniappan Senthil

Introduction: Congenital hyperinsulinism (CHI) is a rare genetic disorder that is characterised by persistent hypoglycaemia in infants and children. We are reporting a rare case of diffuse CHI who was also found to have hypopituitarism and several other congenital anomalies. A similar association has not been reported in literature.Case: A female baby was born at 42 weeks gestation with a birth weight of 4.185 kg (1.72SDS). She suffered shoulder dystocia...

hrp0084p3-1114 | Pituitary | ESPE2015

Management of Risperidone Induced Hyperprolactinemia in an Adolescent with Severe Autism

Giri Dinesh , Sanam Tayyaba , Oppenheim A , Senniappan Senthil , Das Urmi

Background: Risperidone is a second-generation antipsychotic medication, which inhibits dopamine and serotonin receptors. Around half of children and adolescents treated with risperidone develop hyperprolactinemia. Chronic hyperprolactinemia can lead to osteoporosis, cardiovascular disease and delayed growth and puberty. There is no available guidance on management of antipsychotic induced hyperprolactinemia in children. We describe the challenges in the management of a teenag...

hrp0094p1-76 | Fetal Endocrinology and Multisystem Disorders A | ESPE2021

Hyperinsulinemic Hypoglycemia in a child with Peroxisomal Biogenesis Disorder due to a Novel PEX1 mutation

Lohiya Nikhil , Morris Andrew , Didi Mohamed , Senniappan Senthil ,

Introduction: Peroxisomal biogenesis disorders - Zellweger Syndrome Spectrum (PBD-ZWS) are rare disorders involving multiple systems including the central nervous system, adrenals, liver and skeleton but hyperinsulinism is not a recognized association. We present a child with PBD-ZWS due to a novel mutation in PEX1 who developed hyperinsulinaemic hypoglycaemia (HH).Case report: A 7 month old boy presented with recurrent hypoglyc...

hrp0097p1-51 | Fat, Metabolism and Obesity | ESPE2023

GLP1 agonists improve glycaemic dysregulation, satiety levels and quality of life in adolescents with obesity

Apperley Louise , Parkinson Jennifer , Senniappan Senthil , Patrizia Bruzzi

Introduction: GLP-1 receptor agonists (GLP1A) have been shown to be effective in achieving weight loss in adolescents with obesity and improve glycaemic control in type 2 diabetes mellitus (T2DM). We aimed to investigate the glycaemic alterations and satiety levels in patients treated with the GLP1A, liraglutide. To the best of our knowledge, this is the first study of its kind.Methods: In total, 22 patients managed in a...

hrp0098p1-139 | Fat, Metabolism and Obesity 2 | ESPE2024

The effect of pharmacotherapy compared to lifestyle intervention on body composition in children and young people managed within a multidisciplinary weight management service

Dixon Hannah , Apperley Louise , Senniappan Senthil , Parkinson Jennifer

Introduction: Children and adolescents with a body mass index (BMI) greater than the 98th centile are at an increased risk of complications including cardiovascular and liver disease and type 2 diabetes mellitus. Currently, lifestyle modification is the first line intervention. Pharmacotherapy, such as liraglutide and semaglutide, has recently been licensed for adolescents greater than 12 years of age. This study aimed to compare the impact of pharmacotherapy ...

hrp0098p2-17 | Adrenals and HPA Axis | ESPE2024

17OHP and cortisol day curve profiles for children using hard-capsule modified release hydrocortisone as compared with immediate release hydrocortisone.

Petkovic Grace , Blair Joanne , Senniappan Senthil , Park Julie

Background: Childhood adrenal insufficiency (AI) is generally treated with immediate release hydrocortisone (IRH), which has a short half-life, requiring multiple daily doses. Modified-release hard hydrocortisone capsules (Efmody®) (MRH) is licenced for use in children >12yrs with congenital adrenal hyperplasia (CAH).Aims: (1) Describe the characteristics of children switched to MRH; (2) Report blood spot 17-hydro...

hrp0095p1-10 | Adrenals and HPA Axis | ESPE2022

Outcomes of the low dose short Synacthen test in infancy

Park Julie , Jones Lily , Dharmaraj Poonam , Senniappan Senthil , Morgan Colin , Hawcutt Daniel , Blair Joanne

Background: The hypothalamic-pituitary-adrenal (HPA) axis may be suppressed at birth. In most infants this is tolerated well. HPA testing in infancy often generates ‘abnormal’ results although abnormalities of the HPA may not be identified and cortisol measurements often ‘normalise’ over time.[1]Aim: To contribute to the evidence base on neonatal HPA activity by reporting outcomes of infants age &...

hrp0095p1-267 | Fat, Metabolism and Obesity | ESPE2022

Feasibility of integrating an mHealth intervention to increase exercise and physical activity adherence into a weight management service for adolescents with severe obesity: MOTIVATE-WMA

Davies Andrew , Hesketh Katie , Clarke Ellie , Apperley Louise , Sprung Victoria , Jones Helen , Senniappan Senthil , Cocks Matthew

Introduction: The Royal College of Paediatrics and Child Health state that adolescents with significant obesity require access to evidence-based weight management services (WMS). Due to the known benefits of exercise and physical activity (PA) on physiological and psychological outcomes increasing exercise and PA should form a cornerstone of any WMS for adolescents living with obesity. However, supervised exercise interventions face challenges within a clinica...

hrp0092fc9.2 | Fetal, Neonatal Endocrinology and Metabolism (to include Hypoglycaemia) | ESPE2019

Heterozygous Insulin Receptor (INSR) Mutation associated with Neonatal Hyperinsulinaemic Hypoglycaemia and Familial Diabetes Mellitus

Sethi Aashish , Ahmed Syed Haris , Colclough Kevin , Didi Mohammed , Flanagan Sarah , Senniappan Senthil

Introduction: Mutations in Insulin Receptor (INSR) is usually associated with insulin resistance and hyperglycemia. Homozygous or compound heterozygous mutations in INSR are usually linked with Rabson-Mendenhall or Donohue syndromes whilst heterozygous INSR mutations are associated with type A insulin resistance. Various autosomal dominant heterozygous INSR mutations leading to hyperinsulinemic hypoglycemia (HH) have been de...